ODEVIXIBAT SESQUIHYDRATE (Bylvay®)
Clinical Indication
Treatment of progressive familial intrahepatic cholestasis in patients aged 6 months or older.
Date of classification
April 2022
Grey
Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.
- New medicines, devices, appliances.
- New indication of existing medicine.
- New NICE TA which has not been reviewed.
- Not been requested for review by either TAS/LPT MMC.